विदेश

Oct 1 (Reuters) – DDMP REIT Inc: * DECLARES REGULAR CASH DIVIDEND OF 0.023702 PESOS PER SHARE TO BE PAID ON NOVEMBER 26 Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Refiles to add dateline) Oct 1 (Reuters) – Major Gulf stock markets opened with mixed performance on Wednesday, as the U.S. government shutdown raised concerns about the delay in the release of crucial jobs data, clouding future interest rate trends. The U.S. government shut down much of its operations as deep partisan divisions prevented Congress and the White House from reaching a funding deal, setting off what could be a long, grueling standoff that could lead to the loss of thousands of federal jobs. The shutdown could delay the release of key economic data, including the non-farm payrolls report due on Friday. Monetary policy shifts in the U.S. have a significant impact on Gulf markets, where most currencies are pegged to the dollar. Saudi Arabia's benchmark index gained 0.1%, with Saudi Arabian Mining Company gaining 1.1%. In Abu Dhabi, the index eased 0.1%, hit by a 2.9% fall in ADNOC Distribution as the firm traded ex-dividend. Oil prices – a catalyst for the Gulf's financial markets – steadied after two days of declines as investors weighed OPEC+ plans for a larger output hike next month and the outcome of a U.S. government shutdown that could impact economic activity and fuel demand. Dubai's benchmark DFM General Index rose 0.5%, buoyed by gains in key stocks. Blue-chip real estate developer Emaar Properties climbed 1.9%. Supermarket operator Spinneys surged 2.6% following the announcement of its joint venture with Ayala Corp. to introduce premium grocery stores in the Philippines. The Qatari benchmark dropped 0.8%, hit by a 1.2% fall in the Gulf's biggest lender Qatar National Bank. (Reporting by Ateeq Shariff in Bengaluru; Editing by Janane Venkatraman)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

* 'It's a very strong move,' says former Netanyahu adviser * Right-wing allies oppose mention of Palestinian statehood * Plan may shore up Netanyahu's base ahead of 2026 vote * Hamas faces pressure to accept plan or face siege By Alexander Cornwell and May Angel TEL AVIV/JERUSALEM, Oct 1 (Reuters) – Israeli Prime Minister Benjamin Netanyahu’s support for Donald Trump’s Gaza plan is a gamble that may win back estranged allies abroad and repair his political base at home but risks a battle with coalition partners opposed to any hint of a Palestinian state. Netanyahu, aligning himself with Trump, framed the plan as a joint effort that advances his government's goals while shifting international criticism about the war onto Hamas, which must now choose between accepting it or facing continued siege. The move could shore up Netanyahu's support at home by ending an increasingly unpopular war and winning the release of hostages still held by the Palestinian militant group, bolstering his chances at elections due in a year's time. But the plan's reference to a Palestinian state is likely to antagonise members of Netanyahu's governing coalition, the most right-wing in Israel's history, where ultra-nationalist allies Itamar Ben-Gvir and Bezalel Smotrich hold outsized influence. PLAN PUTS ALL PRESSURE ON HAMAS, ASKS LITTLE OF ISRAEL Nadav Shtrauchler, a former adviser to Netanyahu, called the deal a "win-win" for the prime minister, saying that it shifts all the pressure onto Hamas while easing international scrutiny of Israel, and leaves coalition critics with no alternative. "For him, it's checkmate. It's a very strong move," he said, that could see Netanyahu enter the next election with the hostages released and Israel's push to expand ties with Arab and Muslim nations, a process derailed by the war in Gaza, revived. Trump's proposal, quickly endorsed by leaders across the Arab and Muslim world, asks little of Israel in the short term. Instead, it puts all the pressure on Hamas, demanding the freedom for all of the remaining hostages and the surrender of its weapons as a precondition for ending Israel's siege of Gaza. Israel's military would remain in Gaza for now, pulling back to positions along the border only once an international force assumes control. Netanyahu, who has insisted that Israel must retain overall security control after the war, said on Tuesday the military would stay in most of Gaza but offered no timeline. COALITION PARTNER SLAMS PLAN AS 'POLITICAL ILLUSIONS' In a lengthy post on X on Tuesday, Smotrich, who has openly called for Israel's Gaza campaign to continue, denounced Trump's plan, arguing it would trade "real achievements on the ground for political illusions". His Religious Zionism party holds seven of the Knesset's 120 seats, though recent polls indicate that he would struggle to win any if elections were held today. Israel's war in Gaza, launched in response to Hamas' October 2023 surprise attack, has lost support among much of the public. A survey published on Tuesday by the Jerusalem-based Israel Democracy Institute found that 66% of Israelis believe that it is time to end the war, including 48.5% on the political right. Eran Lerman, a former deputy national security adviser, said that Netanyahu knows Hamas' acceptance of Trump's plan could shatter his ruling coalition, but may still hope to be able to face voters with "a very different perspective on what happened over the last two years" than he would able to present today. "I'm not sure that this is true, but you know, politicians are easily tempted to believe in things that cohere with their ambitions," said Lerman, who is also vice president of the Jerusalem Institute for Strategy and Security think tank. Israel's opposition, made up of right, center and left parties, has also called for an end to the war and is often critical of Smotrich and Ben-Gvir, another far-right minister with outsized coalition influence. Many have also ruled out joining a future coalition with Netanyahu’s ultra-Orthodox allies over their communities' refusal to serve in the military. A source briefed on the matter said that Netanyahu would not bring Trump's 20-point plan to government for approval and would instead ask ministers only to vote on the terms to free the hostages. Israel is to free hundreds of Palestinian detainees in exchange. Former Israeli diplomat Alon Pinkas cautioned that Netanyahu would likely draw out negotiations on issues that remain ambiguous, such as the withdrawal of Israel's military, with the aim of both surviving politically and undermining Trump's plan. FOR NETANYAHU, ARAB ALLIANCES MAY OUTFLANK RIGHT-WING FURY Israel has faced mounting international isolation over the nearly two-year-old war in Gaza. This month, some of its closest allies have formally recognized a Palestinian state despite Israeli objections, while others have sanctioned senior government ministers and imposed bans on weapons transfers to Israel. Hamas, for its part, has little diplomatic leverage. It can accept the terms or try to negotiate, but that would risk the plan being enforced in areas it no longer controls while Trump gives Israel a green light to continue attacking the group. A source briefed on the matter said that Netanyahu had pushed to remove a reference in Trump's plan to Palestinian statehood, which the Israeli leader has said would never happen. The document does not offer a clear path to statehood. Instead, it says that as Gaza is rebuilt and once the Palestinian Authority's reform program is "faithfully carried out", conditions "may finally be in place for a credible pathway to Palestinian self-determination and statehood, which we recognize as the aspiration of the Palestinian people." That language is likely to anger many of Netanyahu's right-wing coalition allies, who had publicly warned ahead of his meeting with Trump against any mention of a Palestinian state. But standing beside Trump, Netanyahu said the document laid the groundwork for dramatically advancing peace in the region and beyond, signaling both leaders' ambitions to expand Israel's ties with Muslim states that still do not recognize it. Neve Gordon, an Israeli scholar at Queen Mary University of London, said that Netanyahu likely believes he can win the next election, scheduled to be held by October 2026, if he has a plan in place to normalise ties with more Arab and Muslim states. But he cautioned that even after accepting Trump’s plan, Netanyahu could later break from it and place the blame on Hamas, a tactic the Israeli scholar noted he has used before, and which could even strengthen his standing politically. (Reporting by Alexander Cornwell in Tel Aviv and May Angel in Jerusalem, additional reporting by Steven Scheer in Jerusalem, Editing by William Maclean)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

MADRID, Oct 1 (Reuters) – The Bank of Spain said on Wednesday it had approved an increase in the countercyclical capital buffer to 1.0% from 0.5%, coming into effect on October 1, 2026. The buffer seeks to mitigate or prevent cyclical risks caused by excessive growth in aggregate credit by requiring lenders to build insurance reserves during times of strong growth which would then be available in the case of a downturn. Until now, the buffer was only activated when risks were high, but now it will be applied when risks are at an intermediate level as they currently are, the central bank said. (Reporting by Jesús Aguado, editing by Andrei Khalip)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Adds more details in paragraphs 2-8 and reason for growth in paragraph 1) By Siyanda Mthethwa JOHANNESBURG, Oct 1 (Reuters) – South African lender Capitec Bank reported a 26% increase in half-year profit on Wednesday driven by a strong performance across its banking, insurance, and fintech segments. Alongside a sharp rise in active customers, the profit increase reinforces its position as the country's largest retail bank by customer base. Headline earnings per share, a key profitability metric in South Africa, rose to 8 billion rand ($464.37 million) for the six months ended August 31, from 6.4 billion rand in the same period last year. The bank grew its client base to 25 million, up from 23 million a year ago. Net interest income after credit impairments rose by 27% to 7.1 billion rand, reflecting increased earnings from loans relative to interest paid on deposits. Net non-interest income rose 19% to 13.4 billion rand. "Our ability to leverage economies of scale, simplify transaction costs, and innovate across our offerings has made a meaningful difference for our clients while delivering strong financial results," said Group CEO Graham Lee, who officially succeeded Capitec founder Gerrie Fourie in June 2025. Loan disbursements grew by 40% during the period, supported by a 32% rise in personal banking loans and a 42% increase in business banking loans. Capitec posted a 36% surge in income from value-added services and a 45% increase in net insurance income, driven by higher sales of funeral and life cover policies. It declared an interim dividend of 26.20 rand per share, a 26% increase from 20.85 rand a year earlier. ($1 = 17.2277 rand) (Reporting by Siyanda Mthethwa;Editing by Sfundo Parakozov, Muralikumar Anantharaman and Christian Schmollinger)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

* US patients often pay nearly three times more than in other developed nations for prescription drugs * Pfizer first drug company to announce a deal with the Trump administration * Pfizer shares rise more than 6%, other drugmakers also up * White House plans a direct-to-consumer website for Americans to buy drugs (Adding European shares in 3rd paragraph, detail on Pfizer's global footprint and drugmakers' pledges on US output in paragraphs 12 and 13) By Nandita Bose and Patrick Wingrove WASHINGTON, Sept 30 (Reuters) – Pfizer and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief. Trump also said Pfizer would offer that most-favored-nation pricing on all new drugs launched in the U.S. and flagged that other drugmakers will follow suit. Shares of Pfizer rose more than 6% on Tuesday, and the news lifted Eli Lilly, Merck, Amgen, AbbVie and GSK shares as well on investor relief that they would escape the worst of tariffs. European shares rose in early Wednesday trade. U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere. TRUMPRX TO LAUNCH IN 2026 Pfizer will be part of the White House's new direct-to-consumer website for Americans to buy drugs, called TrumpRx, that will launch in 2026. "The United States is done subsidizing the healthcare of the rest of the world," Trump said, speaking at an event in the Oval Office accompanied by Pfizer CEO Albert Bourla, Health Secretary Robert F. Kennedy Jr. and others. Several drugmakers have already set up direct-to-consumer pricing for some of their drugs, to be listed on a new website from the U.S. lobby group PhRMA, and raised the prices of their therapies in Britain in line with Trump's desire to offset price decreases in the U.S. On September 25, Trump announced he would impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a drugmaker is building a manufacturing plant in the U.S. PFIZER DEAL INCLUDES 3-YEAR GRACE PERIOD Pfizer is the first drugmaker to announce a deal. Trump sent letters to 17 leading drug companies in July telling them to slash prices to match those paid overseas. He asked them to respond with binding commitments by September 29. Sources at five large drugmakers told Reuters the Trump-Pfizer announcement caught their companies by surprise and that they watched the White House press conference to gauge its implications. Pfizer will invest $70 billion in research and development and domestic manufacturing and received a three-year grace period during which its products will not be subject to the pharmaceutical-targeted tariffs, "as long as, of course, we move the products here," Bourla said. Pfizer has about nine manufacturing sites in the United States and 28 in other parts of the world, from Ireland to Japan, according to its website. Pfizer's rivals including AstraZeneca and Eli Lilly have in recent months made similar pledges to boost their U.S. manufacturing capacity after Trump's threats on tariffs. Pfizer said a large majority of its primary care treatments and some select specialty brands will be offered at savings that will range as high as 85% and on average 50%. According to a poster on display at the event, those will include rheumatoid arthritis drug Xeljanz, which carries a list price of over $6,000 a month, migraine treatment Zavzpret, dermatitis drug Eucrisa and post-menopausal osteoporosis medication Duavee. Drugmakers' shares rose because the price concessions are limited to Medicaid, said Daniel Barasa, portfolio manager at investment firm Gabelli Funds. Barasa said the deal was "a highly favorable outcome for the industry. Given that Medicaid already benefits from substantial discounts and rebates – exceeding 80% in certain cases – the incremental impact on manufacturers is relatively minimal." LAUNCHING NEXT YEAR New Medicaid prices are also set to launch in 2026, a senior administration official said on a media call. The most-favored-nation pricing is based on the lowest price paid in eight other wealthy countries after fees and rebates. More than 70 million people are covered by Medicaid, the state and federal government program for low-income people. But drug spending in the program is dwarfed by that of its sister program Medicare, which covers people aged 65 and older or who have disabilities and is not included in Tuesday's announcement. Medicare's drug spending reached $216 billion in 2021, while Medicaid's gross spending was around $80 billion. Anna Kaltenboeck, a health economist at Verdant Research, said that if Pfizer and other companies provide supplemental rebates to Medicaid, that could be significant, as it would support states struggling with the cost of specialty drugs. Medicaid spends less on drugs than other payers, however, so the impact would be less dramatic than if the reductions applied to Medicare, she said. (Reporting by Nandita Bose, Jarrett Renshaw, Katherine Jackson and Susan Heavey in Washington; Maggie Fick in London; Patrick Wingrove in New York, Sneha S K in Bengaluru and Deena Beasley in Los Angeles; Writing by Michael Erman in New Jersey; Editing by Bill Berkrot, Elaine Hardcastle)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Oct 1 (Reuters) – Karur Vysya Bank Ltd: * TOTAL DEPOSITS AS ON SEPT 30 UP 15.29% Y/Y * ADVANCES AS OF 30.09.2025 UP 15.47% YOY Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Oct 1 (Reuters) – CSL Finance Ltd: * REPORTS 27.4% YOY GROWTH WITH AUM QUARTER ENDED SEPT Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

POLAND SAYS IT WILL EXTEND CONTROLS ON BORDERS WITH GERMANY AND LITHUANIA UNTIL APRIL 4

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

CORRECTED-SPOT GOLD EXTENDS GAINS, LAST UP NEARLY 1% TO $3,895.09/OZ (NOT $3,95.09)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)